Psychedelics-Focused Compass Pathways Has Established Itself As ‘Credible CNS Biotechnology Company,’ Analyst Says

Compass Pathways gains Stifel’s Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026. Latest Ratings for CMPS Date Firm Action From To Nov 2021 HC Wainwright & Co. Maintains Buy Oct 2021 Oppenheimer Initiates Coverage On Outperform Jul 2021 Citigroup Initiates Coverage On Buy View…

Read More

Urban Outfitters Tops Q4 Estimates, But Analyst Stays Neutral Amid Weather-Driven Demand Shifts

J.P. Morgan analyst Matthew R. Boss raised Urban Outfitters price target from $54 to $56, maintaining a Neutral rating. The company reported Q4 adjusted EPS of $1.04, surpassing expectations. This was driven by a 16.8% YoY gross profit increase, beating forecasts. Latest Ratings for URBN Date Firm Action From To Mar 2022 Morgan Stanley Maintains…

Read More